

Gary Remington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2123647/publications.pdf>

Version: 2024-02-01

225
papers

13,955
citations

26630

56
h-index

23533

111
g-index

225
all docs

225
docs citations

225
times ranked

10467
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2000, 157, 514-520.	7.2	982
2	Serotonin-dopamine interaction and its relevance to schizophrenia. <i>American Journal of Psychiatry</i> , 1996, 153, 466-476.	7.2	820
3	A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients. <i>Journal of Clinical Psychopharmacology</i> , 1993, 13, 25-40.	1.4	707
4	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
5	Clinical and Theoretical Implications of 5-HT ₂ and D ₂ Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia. <i>American Journal of Psychiatry</i> , 1999, 156, 286-293.	7.2	600
6	Negative Symptoms in Schizophrenia: Avolition and Occam's Razor. <i>Schizophrenia Bulletin</i> , 2010, 36, 359-369.	4.3	504
7	A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy. <i>Archives of General Psychiatry</i> , 2000, 57, 553-559.	12.3	431
8	Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. <i>Biological Psychiatry</i> , 2001, 50, 873-883.	1.3	339
9	Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia. <i>Annual Review of Medicine</i> , 2001, 52, 503-517.	12.2	293
10	Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 753-760.	1.9	222
11	Increased Stress-Induced Dopamine Release in Psychosis. <i>Biological Psychiatry</i> , 2012, 71, 561-567.	1.3	222
12	Guidelines for the Pharmacotherapy of Schizophrenia in Adults. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 604-616.	1.9	212
13	The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study. <i>Life Sciences</i> , 1995, 57, PL103-PL107.	4.3	204
14	Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. <i>Journal of Psychiatric Research</i> , 2014, 48, 102-110.	3.1	204
15	An Algorithm-Based Approach to First-Episode Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1439-1444.	2.2	186
16	Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders. <i>European Neuropsychopharmacology</i> , 2014, 24, 693-709.	0.7	171
17	Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2017, 43, 764-777.	4.3	159
18	A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 2001, 158, 1305-1313.	7.2	154

#	ARTICLE	IF	CITATIONS
19	Impact of primary negative symptoms on functional outcomes in schizophrenia. <i>European Psychiatry</i> , 2014, 29, 449-455.	0.2	153
20	Significant dissociation of brain and plasma kinetics with antipsychotics. <i>Molecular Psychiatry</i> , 2002, 7, 317-321.	7.9	152
21	Atypical antipsychotics: are some more atypical than others?. <i>Psychopharmacology</i> , 2000, 148, 3-15.	3.1	150
22	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. <i>Psychiatry Research</i> , 2012, 197, 1-6.	3.3	148
23	Equivalent Occupancy of Dopamine D ₁ and D ₂ Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics. <i>American Journal of Psychiatry</i> , 2004, 161, 1620-1625.	7.2	146
24	The use of electronic monitoring (MEMS [®]) to evaluate antipsychotic compliance in outpatients with schizophrenia. <i>Schizophrenia Research</i> , 2007, 90, 229-237.	2.0	128
25	Treating Negative Symptoms in Schizophrenia: an Update. <i>Current Treatment Options in Psychiatry</i> , 2016, 3, 133-150.	1.9	123
26	Motivational Deficits and Cognitive Test Performance in Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 1058.	11.0	122
27	Motivational deficits in early schizophrenia: Prevalent, persistent, and key determinants of functional outcome. <i>Schizophrenia Research</i> , 2015, 166, 9-16.	2.0	120
28	The relationship between D ₂ receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. <i>Psychopharmacology</i> , 1997, 131, 148-152.	3.1	118
29	Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1036-1042.	5.4	116
30	Glutamate-mediated excitotoxicity in schizophrenia: A review. <i>European Neuropsychopharmacology</i> , 2014, 24, 1591-1605.	0.7	115
31	Methamphetamine Use and Schizophrenia: A Population-Based Cohort Study in California. <i>American Journal of Psychiatry</i> , 2012, 169, 389-396.	7.2	114
32	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [¹⁸ F]FEPPA. <i>American Journal of Psychiatry</i> , 2017, 174, 118-124.	7.2	103
33	Depression in schizophrenia: a comparison of three measures. <i>Schizophrenia Research</i> , 1996, 20, 205-209.	2.0	97
34	Motivational deficits as the central link to functioning in schizophrenia: A pilot study. <i>Schizophrenia Research</i> , 2009, 115, 333-337.	2.0	96
35	Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry</i> , 2019, 85, 596-605.	1.3	94
36	Augmentation Strategies in Clozapine-Resistant Schizophrenia. <i>CNS Drugs</i> , 2005, 19, 843-872.	5.9	87

#	ARTICLE	IF	CITATIONS
37	Early Use of Clozapine for Poorly Responding First-Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 369-373.	1.4	82
38	Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?. <i>Psychopharmacology</i> , 2013, 225, 505-518.	3.1	79
39	Further Neuroimaging Evidence for the Deficit Subtype of Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 446.	11.0	79
40	Alterations of dopamine and serotonin transmission in schizophrenia. <i>Progress in Brain Research</i> , 2008, 172, 117-140.	1.4	75
41	Neuroimaging findings in treatment-resistant schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2015, 164, 164-175.	2.0	75
42	Progress in Defining Optimal Treatment Outcome in Schizophrenia. <i>CNS Drugs</i> , 2010, 24, 9-20.	5.9	74
43	The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy?. <i>Neuroscience and Biobehavioral Reviews</i> , 2002, 26, 361-380.	6.1	72
44	Are Animal Studies of Antipsychotics Appropriately Dosed?: Lessons from the Bedside to the Bench. <i>Canadian Journal of Psychiatry</i> , 2000, 45, 241-246.	1.9	70
45	Pharmacotherapy of first-episode schizophrenia. <i>British Journal of Psychiatry</i> , 1998, 172, 66-70.	2.8	68
46	Using Treatment Response to Subtype Schizophrenia: Proposal for a New Paradigm in Classification. <i>Schizophrenia Bulletin</i> , 2013, 39, 1169-1172.	4.3	68
47	Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 215-222.	1.9	63
48	Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to <i>N</i> -Desmethylclozapine. <i>American Journal of Psychiatry</i> , 2015, 172, 579-585.	7.2	63
49	The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. <i>Psychiatry Research</i> , 2018, 268, 114-122.	3.3	62
50	Antipsychotic Dosing: How Much but also How Often?. <i>Schizophrenia Bulletin</i> , 2010, 36, 900-903.	4.3	60
51	Genetics of Antipsychotic-induced Side Effects and Agranulocytosis. <i>Current Psychiatry Reports</i> , 2011, 13, 156-165.	4.5	60
52	Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1193-1203.	2.4	60
53	Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. <i>Journal of Psychiatry and Neuroscience</i> , 2003, 28, 275-84.	2.4	60
54	Clozapine's Role in the Treatment of First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2013, 170, 146-151.	7.2	59

#	ARTICLE	IF	CITATIONS
55	Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv014-pyv014.	2.1	59
56	The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. <i>Psychopharmacology</i> , 2003, 165, 166-171.	3.1	58
57	Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: Resting state functional connectivity. <i>Schizophrenia Research</i> , 2014, 160, 43-50.	2.0	58
58	â€œExtendedâ€•Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1042-1048.	2.2	58
59	Tardive dyskinesia: eliminated, forgotten, or overshadowed?. <i>Current Opinion in Psychiatry</i> , 2007, 20, 131-137.	6.3	57
60	Motivated to do well: An examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. <i>Schizophrenia Research</i> , 2015, 166, 276-282.	2.0	57
61	Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis. <i>CNS Drugs</i> , 2020, 34, 579-598.	5.9	55
62	Antipsychotics and glucose metabolism: how brain and body collide. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E1-E15.	3.5	54
63	Where to Position Clozapine: Re-Examining the Evidence. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 677-684.	1.9	52
64	Treatment Recommendations for Tardive Dyskinesia. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 388-399.	1.9	52
65	Differential Effects of Within-Day Continuous Vs Transient Dopamine D2 Receptor Occupancy in the Development of Vacuous Chewing Movements (VCMs) in Rats. <i>Neuropsychopharmacology</i> , 2003, 28, 1433-1439.	5.4	51
66	Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 656-661.	1.9	50
67	Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuropsychopharmacology</i> , 2020, 45, 632-640.	5.4	50
68	Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 340-352.	4.8	49
69	The Assessment and Treatment of Antipsychotic-Induced Akathisia. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 719-729.	1.9	48
70	Insight and subjective measures of quality of life in chronic schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 127-132.	1.3	47
71	Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2012, 140, 214-220.	2.0	46
72	Emerging drugs for schizophrenia. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 479-495.	2.4	45

#	ARTICLE	IF	CITATIONS
73	Happiness in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2012, 141, 98-103.	2.0	45
74	Antipsychotics and Amotivation. <i>Neuropsychopharmacology</i> , 2015, 40, 1539-1548.	5.4	45
75	Dissecting negative symptoms in schizophrenia: Opportunities for translation into new treatments. <i>Journal of Psychopharmacology</i> , 2015, 29, 116-126.	4.0	44
76	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw181.	4.3	44
77	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. <i>Molecular Psychiatry</i> , 2022, 27, 2950-2967.	7.9	44
78	Effort-based decision making as an objective paradigm for the assessment of motivational deficits in schizophrenia. <i>Schizophrenia Research</i> , 2015, 168, 483-490.	2.0	43
79	Life satisfaction and happiness among young adults with schizophrenia. <i>Psychiatry Research</i> , 2016, 242, 174-179.	3.3	41
80	Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. <i>British Journal of Psychiatry</i> , 2011, 199, 275-280.	2.8	40
81	The Effect of Clozapine on Hematological Indices. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 510-516.	1.4	40
82	A meta-analysis of transcranial direct current stimulation for schizophrenia: "œels more better?â€ <i>Journal of Psychiatric Research</i> , 2019, 110, 117-126.	3.1	40
83	Predictors and markers of clozapine response. <i>Psychopharmacology</i> , 2005, 179, 317-335.	3.1	39
84	The crossover approach to switching antipsychotics: What is the evidence?. <i>Schizophrenia Research</i> , 2005, 76, 267-272.	2.0	37
85	Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. <i>European Neuropsychopharmacology</i> , 2013, 23, 1017-1022.	0.7	37
86	Clozapine and Global Cognition in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 431-436.	1.4	35
87	Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study. <i>Schizophrenia Research</i> , 2013, 151, 203-208.	2.0	35
88	Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 515-522.	1.9	35
89	Genetics of tardive dyskinesia: Promising leads and ways forward. <i>Journal of the Neurological Sciences</i> , 2018, 389, 28-34.	0.6	35
90	Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. <i>NPJ Schizophrenia</i> , 2021, 7, 22.	3.6	35

#	ARTICLE	IF	CITATIONS
91	Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 11-22.	3.2	34
92	One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 211, 137-143.	2.8	33
93	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2015, 161, 351-356.	2.0	32
94	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 208, 420-429.	2.0	32
95	Estimating Endogenous Dopamine Levels at D2 and D3 Receptors in Humans using the Agonist Radiotracer [11C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2014, 39, 2769-2776.	5.4	31
96	Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. <i>Journal of Psychiatric Research</i> , 2020, 124, 151-158.	3.1	31
97	The neurobiology of relapse in schizophrenia. <i>Schizophrenia Research</i> , 2014, 152, 381-390.	2.0	30
98	"Extended" Antipsychotic Dosing. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 611-613.	1.4	29
99	Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. <i>Psychopharmacology</i> , 2014, 231, 2237-2249.	3.1	28
100	Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. <i>Neuropsychopharmacology</i> , 2017, 42, 2259-2271.	5.4	28
101	Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. <i>Schizophrenia Research</i> , 2014, 153, 184-188.	2.0	27
102	Investigating consummatory and anticipatory pleasure across motivation deficits in schizophrenia and healthy controls. <i>Psychiatry Research</i> , 2017, 254, 112-117.	3.3	27
103	Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 78, 140-148.	4.8	27
104	Management of Schizophrenia in Late Life with Antipsychotic Medications. <i>Drugs and Aging</i> , 2011, 28, 961-980.	2.7	26
105	Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. <i>Schizophrenia Research</i> , 2015, 166, 304-309.	2.0	26
106	Reward-driven decision-making impairments in schizophrenia. <i>Schizophrenia Research</i> , 2019, 206, 277-283.	2.0	26
107	Adherence to clozapine vs. other antipsychotics in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 87-95.	4.5	26
108	Conventional versus novel antipsychotics: changing concepts and clinical implications. <i>Journal of Psychiatry and Neuroscience</i> , 1999, 24, 431-41.	2.4	26

#	ARTICLE	IF	CITATIONS
109	Toward a more parsimonious assessment of neurocognition in schizophrenia: A 10-minute assessment tool. <i>Journal of Psychiatric Research</i> , 2014, 52, 50-56.	3.1	25
110	Development and Reliability Testing of a Health Action Process Approach Inventory for Physical Activity Participation among Individuals with Schizophrenia. <i>Frontiers in Psychiatry</i> , 2014, 5, 68.	2.6	24
111	Investigating the predictors of happiness, life satisfaction and success in schizophrenia. <i>Comprehensive Psychiatry</i> , 2018, 81, 42-47.	3.1	23
112	Rational pharmacotherapy in early psychosis. <i>British Journal of Psychiatry</i> , 2005, 187, s77-s84.	2.8	22
113	Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 95-99.	1.4	22
114	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , 2015, 161, 429-433.	2.0	22
115	Behavioral effects of food-derived opioid-like peptides in rodents: Implications for schizophrenia?. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 134, 70-78.	2.9	22
116	Motivational deficits in major depressive disorder: Cross-sectional and longitudinal relationships with functional impairment and subjective well-being. <i>Comprehensive Psychiatry</i> , 2016, 66, 31-38.	3.1	22
117	Interaction between TSPO“a neuroimmune marker”and redox status in clinical high risk for psychosis: a PET“MRS study. <i>Neuropsychopharmacology</i> , 2018, 43, 1700-1705.	5.4	22
118	Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2020, 46, 1439-1458.	4.3	22
119	Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study. <i>European Neuropsychopharmacology</i> , 2014, 24, 1078-1085.	0.7	21
120	Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw171.	4.3	21
121	D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. <i>Journal of Clinical Psychiatry</i> , 1999, 60 Suppl 10, 15-9.	2.2	21
122	Ethnocultural Factors in Resident Supervision: Black Supervisor and White Supervisees. <i>American Journal of Psychotherapy</i> , 1989, 43, 398-404.	1.2	20
123	Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. <i>Schizophrenia Research</i> , 2016, 176, 411-416.	2.0	20
124	Gas Sniffing as a Form of Substance Abuse. <i>Canadian Journal of Psychiatry</i> , 1984, 29, 31-35.	1.9	19
125	Examining Levels of Antipsychotic Adherence to Better Understand Nonadherence. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 261-263.	1.4	19
126	Baseline social amotivation predicts 1-year functioning in UHR subjects: A validation and prospective investigation. <i>European Neuropsychopharmacology</i> , 2015, 25, 2187-2196.	0.7	19

#	ARTICLE	IF	CITATIONS
127	Measuring motivation in people with schizophrenia. <i>Schizophrenia Research</i> , 2015, 169, 423-426.	2.0	19
128	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene <i>GRIN2B</i> and clinical response to clozapine. <i>Human Psychopharmacology</i> , 2016, 31, 121-134.	1.5	19
129	Adiposity in schizophrenia: A systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 524-536.	4.5	19
130	The Remitting Atypical Psychoses: Clinical and Nosologic Considerations. <i>Canadian Journal of Psychiatry</i> , 1990, 35, 36-40.	1.9	18
131	Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: An animal model. <i>European Neuropsychopharmacology</i> , 2014, 24, 448-458.	0.7	18
132	Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. <i>Schizophrenia Research</i> , 2018, 194, 55-61.	2.0	18
133	Effect of intrinsic motivation on cognitive performance in schizophrenia: A pilot study. <i>Schizophrenia Research</i> , 2014, 152, 317-318.	2.0	17
134	Clozapine administration in clinical practice: once-daily versus divided dosing. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 234-240.	4.5	17
135	Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532210965.	2.7	17
136	Management of Acute Antipsychotic-Induced Extrapyramidal Syndromes. <i>CNS Drugs</i> , 1996, 5, 21-35.	5.9	16
137	Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia. <i>Microbial Biotechnology</i> , 2017, 11, 229-236.	1.7	16
138	Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. <i>Experimental Eye Research</i> , 2018, 175, 32-41.	2.6	16
139	What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy. <i>Neuropharmacology</i> , 2020, 163, 107591.	4.1	16
140	Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109839.	4.8	16
141	Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 506-511.	2.2	16
142	Abbreviated quality of life scales for schizophrenia: Comparison and utility of two brief community functioning measures. <i>Schizophrenia Research</i> , 2014, 154, 89-92.	2.0	15
143	Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. <i>Journal of Psychopharmacology</i> , 2017, 31, 312-319.	4.0	15
144	Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2018, 193, 29-36.	2.0	15

#	ARTICLE	IF	CITATIONS
145	Distress related to subclinical negative symptoms in a non-clinical sample: Role of dysfunctional attitudes. <i>Psychiatry Research</i> , 2015, 230, 249-254.	3.3	14
146	Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings. <i>Psychiatry Research</i> , 2016, 244, 415-419.	3.3	14
147	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. <i>Molecular Neuropsychiatry</i> , 2016, 2, 185-197.	2.9	14
148	Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. <i>Psychiatry Research - Neuroimaging</i> , 2018, 273, 16-24.	1.8	14
149	Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab006.	1.7	14
150	Placebo Response in Refractory Tardive Akathisia. <i>Canadian Journal of Psychiatry</i> , 1993, 38, 248-250.	1.9	13
151	Antipsychotic dosing: found in translation. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 223-231.	2.4	13
152	Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 407-421.	2.4	13
153	Schizophrenia: Antipsychotics and drug development. <i>Behavioural Brain Research</i> , 2021, 414, 113507.	2.2	13
154	Switching atypical antipsychotics: a review. <i>Acta Neuropsychiatrica</i> , 2004, 16, 301-313.	2.1	12
155	Risk of neutropenia in a clozapine-treated elderly population. <i>Schizophrenia Research</i> , 2013, 148, 183-185.	2.0	12
156	Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 881-894.	4.1	12
157	Mean platelet volume in schizophrenia unaltered after 1year of clozapine exposure. <i>Schizophrenia Research</i> , 2014, 157, 134-136.	2.0	12
158	Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. <i>Schizophrenia Research</i> , 2015, 164, 149-154.	2.0	12
159	Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. <i>European Psychiatry</i> , 2019, 61, 63-71.	0.2	12
160	Modeling chronic olanzapine exposure using osmotic minipumps: Pharmacological limitations. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 100, 86-89.	2.9	11
161	Schizophrenia and the influence of male gender. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 578-581.	4.7	11
162	Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. <i>Medical Hypotheses</i> , 2015, 85, 391-396.	1.5	11

#	ARTICLE	IF	CITATIONS
163	A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD). <i>Journal of Psychiatric Research</i> , 2016, 80, 87-92.	3.1	11
164	Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. <i>Schizophrenia Research</i> , 2017, 189, 4-8.	2.0	11
165	Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 523-530.	2.7	11
166	Clozapine-Related Myocarditis and Rechallenge. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 380-385.	1.4	11
167	Revisiting the International Physical Activity Questionnaire (IPAQ): Assessing sitting time among individuals with schizophrenia. <i>Psychiatry Research</i> , 2019, 271, 311-318.	3.3	11
168	You say "schizophrenia" and I say "psychosis". Just tell me when I can come off this medication. <i>Schizophrenia Research</i> , 2020, 225, 39-46.	2.0	11
169	Is Psychiatry Ignoring Suicide?. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 307-308.	1.4	10
170	Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up. <i>Schizophrenia Research</i> , 2015, 169, 69-75.	2.0	10
171	Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. <i>Psychoneuroendocrinology</i> , 2017, 81, 80-87.	2.7	10
172	Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 72, 23-29.	4.8	10
173	A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. <i>Schizophrenia Research</i> , 2018, 194, 47-54.	2.0	10
174	Pharmacotherapy of first-episode schizophrenia. <i>The British Journal of Psychiatry Supplement</i> , 1998, 172, 66-70.	0.1	10
175	GWAS analysis of treatment resistant schizophrenia: interaction effect of childhood trauma. <i>Pharmacogenomics</i> , 2017, 18, 663-671.	1.3	9
176	The neural correlates of apathy in schizophrenia: An exploratory investigation. <i>Neuropsychologia</i> , 2018, 118, 34-39.	1.6	9
177	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109659.	4.8	9
178	Goal-directed planning and action impairments in schizophrenia evaluated in a virtual environment. <i>Schizophrenia Research</i> , 2019, 206, 400-406.	2.0	9
179	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. <i>NeuroImage: Clinical</i> , 2021, 32, 102852.	2.7	9
180	Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, 2.	3.6	9

#	ARTICLE	IF	CITATIONS
181	The Use of Pharmacotherapy in the Prodrome of Schizophrenia. <i>CNS Spectrums</i> , 2004, 9, 579-586.	1.2	8
182	Values in First-Episode Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 507-514.	1.9	8
183	Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. <i>European Neuropsychopharmacology</i> , 2015, 25, 295-302.	0.7	8
184	Improving outcomes in schizophrenia by preventing early relapses. <i>Lancet Psychiatry</i> , 2018, 5, 384-386.	7.4	8
185	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 91-95.	2.6	8
186	Examining strategies to improve accelerometer compliance for individuals living with schizophrenia. <i>Psychiatric Rehabilitation Journal</i> , 2014, 37, 333-335.	1.1	7
187	Use of candidate gene markers to guide antipsychotic dosage adjustment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 315-320.	4.8	7
188	Daily activity patterns in remitted first-episode schizophrenia. <i>Comprehensive Psychiatry</i> , 2014, 55, 1182-1187.	3.1	7
189	Genome-wide association analysis to predict optimal antipsychotic dosage in schizophrenia: a pilot study. <i>Journal of Neural Transmission</i> , 2016, 123, 329-338.	2.8	7
190	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. <i>Neuroscience Letters</i> , 2018, 686, 17-22.	2.1	7
191	Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 223-228.	2.2	7
192	Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 373-383.	1.8	6
193	Relationship between clinical improvement and functional gains with clozapine in schizophrenia. <i>European Neuropsychopharmacology</i> , 2014, 24, 1622-1629.	0.7	6
194	Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. <i>European Neuropsychopharmacology</i> , 2018, 28, 285-296.	0.7	6
195	Augmenting Clozapine Response in Treatment-Resistant Schizophrenia. <i>Advances in Biological Psychiatry</i> , 2010, , 129-151.	0.2	5
196	Assessing analytic and intuitive reasoning using the cognitive reflection test in young patients with schizophrenia. <i>Psychiatry Research</i> , 2020, 284, 112683.	3.3	5
197	What does schizophrenia teach us about antipsychotics?. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S14-8.	1.9	5
198	Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 190-200.	4.5	5

#	ARTICLE	IF	CITATIONS
199	What symptom domains are associated with patient distress in schizophrenia?. Schizophrenia Research, 2016, 176, 329-330.	2.0	4
200	Clozapine and COVID-19. Journal of Psychiatry and Neuroscience, 2020, 45, E1-E1.	2.4	4
201	Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia. Journal of Psychiatric Research, 2021, 136, 468-473.	3.1	4
202	Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Focus (American Psychiatric Publishing), 2016, 14, 396-402.	0.8	3
203	Factors associated with drug attitude in patients with schizophrenia spectrum disorders. Schizophrenia Research, 2017, 188, 185-186.	2.0	3
204	Objective assessment of exploratory behaviour in schizophrenia using wireless motion capture. Schizophrenia Research, 2018, 195, 122-129.	2.0	3
205	Use of Placebo in Clinical Trials of Psychotropic Medication. Canadian Journal of Psychiatry, 2018, 63, 338-341.	1.9	3
206	Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. Journal of Psychopharmacology, 2020, 34, 914-919.	4.0	3
207	Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. Journal of Psychiatry and Neuroscience, 2014, 39, E1-E2.	2.4	2
208	A comparison of cardio-metabolic risk between the deficit and non-deficit subtypes of schizophrenia. Schizophrenia Research, 2014, 153, 246-247.	2.0	2
209	Consistency between clinician and patient ratings of clozapine-induced side effects. Schizophrenia Research, 2016, 174, 200-201.	2.0	2
210	Characterizing the affective responses to an acute bout of moderate-intensity exercise among outpatients with schizophrenia. Psychiatry Research, 2016, 237, 264-270.	3.3	2
211	Clozapine-induced myocarditis in Canada: Evidence from spontaneous reports. Schizophrenia Research, 2019, 206, 462-463.	2.0	2
212	Antipsychotics Circa 2020: What are we thinking?. Neuropharmacology, 2020, 175, 108181.	4.1	2
213	Antipsychotic Medications: Enhancing Use to Improve Outcomes. Schizophrenia Bulletin, 2021, 47, 1201-1204.	4.3	2
214	Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia. Schizophrenia Research: Cognition, 2021, 26, 100205.	1.3	2
215	Reliability of the Clozapine:N-Desmethylclozapine (CLZ:NDMC) Ratio. Schizophrenia Bulletin Open, 2021, 2, .	1.7	2
216	The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans. European Neuropsychopharmacology, 2022, 57, 39-49.	0.7	2

#	ARTICLE	IF	CITATIONS
217	Trait Anhedonia in Schizophrenia: A Systematic Review and Comparative Meta-analysis. Schizophrenia Bulletin, 2022, 48, 335-346.	4.3	2
218	72. Behavioral and Neurobiological Correlates of Attention in Schizophrenia in a Virtual Environment. Schizophrenia Bulletin, 2017, 43, S42-S42.	4.3	1
219	Objective investigation of activity preference in schizophrenia: A pilot study. Psychiatry Research, 2018, 267, 551-559.	3.3	1
220	Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. Psychiatry Research, 2019, 274, 409-413.	3.3	1
221	Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications. Schizophrenia Research, 2021, 237, 202-207.	2.0	1
222	Childhood trauma exposure and personality traits in schizophrenia patients. Schizophrenia Research, 2022, 241, 221-227.	2.0	1
223	Atypical™ antipsychotics: where does ziprasidone fit?. Expert Review of Neurotherapeutics, 2002, 2, 13-24.	2.8	0
224	Measuring the Effects of Treatment With Antipsychotics. JAMA Psychiatry, 2015, 72, 514.	11.0	0
225	Distinct profiles of psychological and neuropsychological functions underlying goal-directed pursuit in schizophrenia. Australian and New Zealand Journal of Psychiatry, 2022, , 000486742210770.	2.3	0